drugset / Trial / NCT02284893

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893

Phase 3 Completed 461 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

Timeline

Start
2014-09-09
Primary completion
2016-09-20
Completion
2016-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral